%0 Journal Article
%T SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study.
%A Tan DHY
%A Tan TL
%A Tan WH
%A Choong C
%A Beekman MJHI
%A Khor JH
%A Kumar SS
%A Wong GR
%A Lim HF
%J BMJ Open
%V 14
%N 6
%D 2024 Jun 10
%M 38858145
%F 3.006
%R 10.1136/bmjopen-2022-064245
%X <B>OBJECTIVE: </B>To evaluate asthma characteristics and treatment patterns, including short-acting β2-agonist (SABA) prescriptions, in primary and specialist care in the Singapore cohort of the SABA use IN Asthma (SABINA III) study.<BR><B>METHODS: </B>Cross-sectional, observational study.<BR><B>METHODS: </B>Multicentre study conducted at five sites across Singapore.<BR><B>METHODS: </B>In patients with asthma (aged ≥12 years), data on demographics, disease characteristics and asthma treatment prescriptions were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by 2017 Global Initiative for Asthma recommendations) and practice type (primary/specialist care).<BR><B>RESULTS: </B>Of the 205 patients analysed (mean (SD) age, 53.6 (16.8) years; female, 62%), 55.9% were enrolled by specialists and 44.1% by primary care physicians. Most study patients (80.5%) had moderate-to-severe asthma (86.0% in specialist care and 74.4% in primary care). In the 12 months before study enrolment, 18.0% of patients experienced ≥1 severe exacerbation. Asthma was well or partly controlled in 78.0% of patients. Overall, 17.1% of all patients were overprescribed SABA (≥3 SABA canisters/year) in the preceding 12 months, and overprescription was greater in specialist versus primary care (26.3% vs 5.6%). Only 2.9% of patients were prescribed SABA monotherapy, while 41.0% received SABA in addition to maintenance therapy. Among the latter, 40.5% were overprescribed SABA. Overall, a higher percentage of patients prescribed ≥3 SABA canisters (vs 0-2 SABA canisters) were assessed as having uncontrolled asthma during the study visit (42.9% vs 17.6%). Maintenance therapy in the form of inhaled corticosteroids (ICS) or ICS/long-acting β2 agonist fixed-dose combinations were prescribed to 14.1% and 84.9% of patients, respectively, in the 12 months before enrolment.<BR><B>CONCLUSIONS: </B>In this Singapore cohort, ~17% of all patients and more than 40% of patients prescribed SABA in addition to maintenance therapy were overprescribed SABA. These findings emphasise the need to align clinical practices with the latest evidence-based treatment recommendations.<BR><B>BACKGROUND: </B>NCT03857178.